Clinical trials: Dense Breasts
Breast - Female, Dense Breast Parenchyma
Evaluation and Reclassification of ( BI-RADS 3) Breast Lesions in Dense Breast
This prospective study aims to compare combined breast ultrasound (US) and digital mammography (DM) with digital breast tomosynthesis (DBT) in the evaluation and reclassification of BI-RADS 3 (probably benign) breast lesions.
- Conditions
- Breast - Female, Dense Breast Parenchyma, Breast Lesion, Digital Mammography
- Trial name
- NCT07804147
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Breast Neoplasms
Delphinus SoftVue Prospective Case Collection - ARM 2
The SoftVue™ is a whole breast ultrasound system with an automated scanning curvilinear ring-array transducer that employs UST. It is currently cleared under FDA 510(k) K123209 and K142517 for use as both a B-mode ultrasonic…
- Trial name
- SV PCC ARM2 (NCT02977247)
- Testing
- Non-Interventional, Automated Whole Breast Ultrasound
- Where
- 10 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Breast Cancer Screening
A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue
Investigation of a tear-based, lab-developed biological test for breast cancer, as a supplemental tool to current screening recommendations for women with dense breast tissue will explore if a tear-based biological test can be…
- Trial name
- NCT05268224
- Testing
- Schirmer Strip
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Namida Lab
Breast Neoplasms
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
The purpose of the study is to address the following hypotheses: (i) Anti-PD-L1 therapy with MEDI4736 administered concomitantly with weekly nab-paclitaxel followed by MEDI4736 concomitant with ddAC neoadjuvant chemotherapy will…
- Trial name
- NCT02489448
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Yale University
Breast Cancer
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2.
- Trial name
- NCT00232479
- Testing
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Miami
Breast Cancer, Early Detection of Cancer
A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
The purpose of this study is to determine the clinical performance of AI-based Thermalytix with the current standard-of-care diagnostic modalities in women.
- Trial name
- NCT04688086
- Testing
- Thermalytix
- Where
- India
- Volunteers
- 687 people, healthy volunteers welcome
- Sponsor
- Niramai Health Analytix Private Limited
Breast Cancer
Tomosynthesis (TS) or Ultrasound (US) in Mammography-negative Dense Breasts (TOMUS). National Multicenter Trial
Breast cancer remains a worldwide big killer with a rate of deaths compared with newly diagnosed cases not lower than 20%. Mammography is the primary imaging modality for the early detection of clinically occult breast cancer.
- Trial name
- TOMUS (NCT03033030)
- Testing
- Ultrasound
- Where
- Italy
- Volunteers
- 8,000 people
- Sponsor
- University of Genova
Breast Cancer Detection, Dense Breast Parenchyma
Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)
The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in…
- Conditions
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening
- Trial name
- DMT SV RRS3 (NCT04260620)
- Testing
- Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Dense Breasts, Breast Cancer
Histology of Functional Density in Premenopausal Breast
The investigators hypothesize that knowledge of the functional behavior of areas of mammographic density will enable more specific identification of dense tissue at-risk for breast cancer, ultimately providing predictive…
- Trial name
- NCT01588834
- Testing
- breast biopsy
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)
In the recent AGO-study, a dose-dense and dose-intensified sequence of Epirubicin - Paclitaxel - Cyclophosphamide has shown superior efficacy compared to a conventionally dosed sequence of Epirubicin / Cyclophosphamid and…
- Trial name
- NCT00196872
- Testing
- Epirubicine, Cyclophosphamide, Taxol
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Investigators propose to study the efficacy of Bevacizumab plus systemic chemotherapy prior to surgery in order to make a locally advanced tumor operable.
- Trial name
- NCT01985841
- Testing
- Bevacizumb, 5-Fluorouracil, Epirubicin
- Where
- 6 sites in Greece
- Volunteers
- 34 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer, Male Breast Cancer
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00470301
- Testing
- tipifarnib, paclitaxel, doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
This study is to evaluate the efficacy and safety for dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 in neoadjuvant therapy for patients with triple-negative…
- Trial name
- NeoTENNIS (NCT04418154)
- Testing
- epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Small Breast Lesions, Dense Breast Tissue
Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions
Detection of breast cancer as early as possible is an ongoing imaging challenge.The purpose of the current study is to assess the clinical performance of the new scintigraphic technology, a dedicated breast gamma camera composed…
- Conditions
- Small Breast Lesions, Dense Breast Tissue, Discrepancy With Clinical Examination, Equivocal Mammographic, Sonographic or MRI Lesion
- Trial name
- NCT01004666
- Where
- Israel
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Asymptomatic
Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts
This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts.
- Trial name
- NCT02933489
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment
- Where
- 68 sites in United States, Germany
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Neoplasms, Breast Cancer
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Previous studies have shown that chemotherapy has the same effect on treating breast cancer whether you receive it before or after surgery.
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast
- Trial name
- NCT01498588
- Testing
- Eribulin, Doxorubicin, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Emory University
Breast Cancer
FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC
The purpose of this study is to assess the feasibility of Ixabepilone (4 cycles) administered every 14 days with the support of G-CSF sequentially to the combination of Fluorouracil, Epirubicin and Cyclophosphamide (4 cycles)…
- Trial name
- GIM9 (NCT00751868)
- Testing
- Ixabepilone
- Where
- 15 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Consorzio Oncotech
Breast Cancer
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy.
- Trial name
- NCT00308178
- Testing
- Abraxane
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Harold J. Burstein, MD, PhD
Breast Cancer
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts
- Trial name
- NCT05667532
- Testing
- Contrast Enhanced Mammography
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Carcinoma
Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat.
- Trial name
- NCT03220893
- Testing
- Digital Breast Tomosynthesis (DBT), Scintimammography
- Where
- 5 sites in United States
- Volunteers
- 3,023 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic